Project/Area Number |
22K07286
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
Research Institution | International University of Health and Welfare |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
三沢 彩 国際医療福祉大学, 医学部, 講師 (20598453)
大多 茂樹 国際医療福祉大学, 医学部, 准教授 (20365406)
河上 裕 国際医療福祉大学, 医学部, 教授 (50161287)
|
Project Period (FY) |
2022-04-01 – 2025-03-31
|
Project Status |
Granted (Fiscal Year 2022)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2024: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2022: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | Immuno-metabolism / Statins / Immunotherapy / tumor microenvironment / Checkpoint inhibitors |
Outline of Research at the Start |
Statins (HMG-CoA reductase inhibitors that inhibit cholesterol synthesis) appear to activate anti-tumor T cells and synergized with ICIs in murine tumor models, and the survivals of lung cancer patients taking statins were prolonged in some observation studies. However, the underlying mechanisms of statins for the enhanced anti-tumor responses remain unclear. Understanding the anti-tumor mechanisms of statins from immuno-metabolic aspects would be helpful for the improvement of the currently using immunotherapies such as immune checkpoint inhibitor combination therapy in cancer patients.
|